Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UP421

Cell therapy · Cell replacement

Early Phase 1 Most advanced trial
1 Registered trials

What is UP421?

UP421 is a cell therapy composed of genetically modified human pancreatic islet cells, delivered by intramuscular transplantation. It is studied in type 1 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Cell replacement
Therapy area
Metabolic
In trials of
SANA
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06239636 Early Phase 1 Type1diabetes Recruiting SANA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type1diabetes

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.